BIOVECTRA and Revolution Biomanufacturing Partner to Deliver Integrated mRNA Design and GMP Production Services

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

Tuberculosis mRNA Vaccine Design Reinvented Using Immunopeptidomics

Despite decades of global vaccination campaigns, Mycobacterium tuberculosis (Mtb) continues to kill more people each year than nearly any other infectious agent, claiming roughly 1.25 million lives in 2023. While the Bacillus Calmette–Guérin (BCG) vaccine protects infants from severe tuberculosis (TB), the century-old treatment offers inconsistent protection for adults. A new study published in Science Translational Medicine describes a major st…